MEDIA

Latest News

Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.

Allure Logo

Every Injectable in Allure Editors’ Faces Right Now

medthority

FDA approves first therapeutic indication for Daxxify for injection for the treatment of cervical dystonia

Patient Worthy

DAXXIFY Now FDA-Approved for the Treatment of Cervical Dystonia

Neurology Live Logo

FDA Approves Expanded Indication of DaxibotulinumtoxinA to Treat Cervical Dystonia

NewBeauty Logo

Daxxify Has Just Received FDA-Approval to Treat This Painful Neck Condition

Reuters Logo

Revance’s Botox rival gets FDA approval for painful neck muscle condition

Medscape

Revance touts first therapeutic indication for Botox rival Daxxify in cervical dystonia

Endpoint News Logo

Revance touts first therapeutic indication for Botox rival Daxxify in cervical dystonia

Scrip

Revance Wins First Daxxify Therapeutic Indication, Plans Limited Initial Rollout

Fierce Farma Logo

Revance pivots into therapeutics with cervical dystonia nod for Botox rival Daxxify

The Wall Street Journal

The Secrets of Women Who Wake Up Looking Beautiful (Hint: It’s Not a Good Night’s Sleep)

Endpoint News Logo

Revance Therapeutics pushes Botox ‘breakup’ in latest campaign for rival cosmetic drug